Patents by Inventor Jeffry D. Watkins

Jeffry D. Watkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20240327532
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: April 24, 2024
    Publication date: October 3, 2024
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
    Patent number: 11999789
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: June 4, 2024
    Assignees: PROMETHEUS BIOSCIENCES, INC., CEDARS-SINAI MEDICAL CENTER
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • NOVEL ROR1 ANTIBODY IMMUNOCONJUGATES
    Publication number: 20230293712
    Abstract: Provided herein are immunoconjugates comprising an anti-ROR1 antibody or an antigen-binding fragment thereof and an exatecan moiety or an analog thereof. These immunoconjugates are useful for treating ROR1-expressing cancers.
    Type: Application
    Filed: July 8, 2021
    Publication date: September 21, 2023
    Applicant: Velosbio Inc.
    Inventors: Brian Lannutti, Katti Jessen, Xin Guo, Mira Ko, Jeffry D. Watkins, Stephanie Louise Johnson, Colin Martin McKee
  • METHODS, SYSTEMS, AND KITS FOR TREATMENT OF INFLAMMATORY DISEASES TARGETING TL1A
    Publication number: 20230272098
    Abstract: Provided are methods, systems, and kits for selecting a subject for treatment with an inhibitor of Tumor necrosis factor-like cytokine 1A (TL1A) activity or expression based on a presence of one or more genotypes associated with a positive therapeutic response to the inhibitor of TL1A. Also provided are methods, systems and kits for detecting the one or more genotypes described herein.
    Type: Application
    Filed: May 12, 2023
    Publication date: August 31, 2023
    Inventors: Laurens KRUIDENIER, Mahyar SABRIPOUR, Jeffry D. Watkins, Cindy T. DICKERSON, Rafael ROJAS, Matthew REISSMAN, Patricia MCNEELEY, Janine BILSBOROUGH, Dermot P. MCGOVERN, Dalin LI
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20230192835
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: September 9, 2022
    Publication date: June 22, 2023
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Optimized anti-TL1A antibodies
    Patent number: 11440954
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: September 13, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20220259320
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: February 28, 2022
    Publication date: August 18, 2022
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • ANTI-ROR1 / ANTI-CD3 BISPECIFIC BINDING MOLECULES
    Publication number: 20220227866
    Abstract: This invention relates to bispecific binding molecules that bind to ROR1 and CD3, and methods of using them to treat diseases and conditions such as cancer.
    Type: Application
    Filed: May 22, 2020
    Publication date: July 21, 2022
    Applicant: VelosBio Inc.
    Inventors: Jeffry D. Watkins, Katti Jessen, Mira Ko, Brian Lannutti, Thanh-Trang Vo, J. Monty Watkins
  • Humanized antibodies to TNF-like ligand 1A (TL1A) and uses thereof
    Patent number: 11292848
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: December 2, 2020
    Date of Patent: April 5, 2022
    Assignees: Prometheus Biosciences, Inc., Cedars-Sinai Medical Center
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley, Janine Bilsborough, Bradley Henkle, Stephan R. Targan
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 11072787
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: July 27, 2021
    Assignee: aTyr Pharma Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • HUMANIZED ANTIBODIES TO TNF-LIKE LIGAND 1A (TL1A) AND USES THEREOF
    Publication number: 20210122828
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: December 2, 2020
    Publication date: April 29, 2021
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, Rafael Rojas, Matthew Reissman, Patricia McNeeley
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20200255510
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF SERYL-TRNA SYNTHETASES
    Publication number: 20200231702
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: November 21, 2019
    Publication date: July 23, 2020
    Inventors: Leslie Ann GREENE, Kyle P. CHIANG, Fei HONG, Alain P. VASSEROT, Wing-Sze LO, Jeffry D. Watkins, Cheryl L. QUINN, John D. Mendlein
  • Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Cysteinyl-tRNA synthetase
    Patent number: 10717786
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: July 21, 2020
    Assignees: aTye Pharma, Inc., Pangu BioPharma Limited
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF ALANYL TRNA SYNTHETASES
    Publication number: 20200223942
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: November 21, 2019
    Publication date: July 16, 2020
    Inventors: Leslie Ann GREENE, Kyle P. CHIANG, Fei HONG, Alain P. VASSEROT, Wing-Sze LO, Jeffry D. Watkins, Cheryl L. QUINN, John D. Mendlein
  • Histidyl-tRNA synthetase-Fc conjugates
    Patent number: 10711260
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: July 14, 2020
    Assignee: aTyr Pharma, Inc.
    Inventors: Chi-Fang Wu, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein
  • Optimized anti-TL1A antibodies
    Patent number: 10689439
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: June 23, 2020
    Assignee: Prometheus Biosciences, Inc.
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF GLUTAMINYL-TRNA SYNTHETASES
    Publication number: 20200172632
    Abstract: Provided are compositions comprising newly identified protein fragments of aminoacyl-tRNA synthetases, polynucleotides that encode them and complements thereof, related agents, and methods of use thereof in diagnostic, drug discovery, research, and therapeutic applications.
    Type: Application
    Filed: September 27, 2019
    Publication date: June 4, 2020
    Inventors: Leslie Ann Greene, Kyle P. Chiang, Fei Hong, Alain P. Vasserot, Wing-Sze Lo, Jeffry D. Watkins, Cheryl L. Quinn, John D. Mendlein
  • OPTIMIZED ANTI-TL1A ANTIBODIES
    Publication number: 20200157203
    Abstract: Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
    Type: Application
    Filed: November 25, 2019
    Publication date: May 21, 2020
    Inventors: Jeffry D. Watkins, Cindy T. Dickerson, J. Monty Watkins
  • HISTIDYL-TRNA SYNTHETASE-FC CONJUGATES
    Publication number: 20200149028
    Abstract: The present invention provides histidyl-tRNA synthetase and Fc region conjugate polypeptides (HRS-Fc conjugates), such as HRS-Fc fusion polypeptides, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The HRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified HRS polypeptides.
    Type: Application
    Filed: September 20, 2019
    Publication date: May 14, 2020
    Inventors: Chi-Fang WU, Darin Lee, Jeffry D. Watkins, Kristi Piehl, Kyle P. Chiang, Marc Thomas, Minh-Ha Do, Ying Buechler, John D. Mendlein